Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Eolas Therapeutics and AstraZeneca have entered into a worldwide license and partnership agreement on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications.
Subscribe to our email newsletter
The company said that the EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the National Institutes of Health (NIH) to develop the program from the preclinical stage through phase I clinical trials.
Eolas Therapeutics CEO Albert Man said: "We are happy to be partnering with AstraZeneca on our EORA program for their scientific, clinical, regulatory, and commercial expertise.
"Our two companies share a vision for greatly improving the lives of patients affected by addiction and other neurological disorders.
"We are also proud to be the first active NIH Blueprint Neurotherapeutics program to bridge the gap from concept to commercial licensing. The BPN has been, and will continue to be, instrumental in the development of our therapeutic program."
The total deal is valued at over $145m and includes upfront, clinical and regulatory milestone payments. In addition, Eolas is eligible to receive royalties on commercial sales.